Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cutting of C5 and preventing the subsequent formation of membrane attack complex, which can be used to study extravascular hemolysis.